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ABSTRACT: 
Background and Purpose: The SOAR stroke score (stroke Subtype, Oxfordshire Community 
Stroke Project classification, Age and pre-stroke modified Rankin scale) is a prognostic 
scale proposed for early mortality prediction following acute stroke. We aimed to evaluate 
whether including a measure of initial stroke severity (National Institutes of Health Stroke 
Scale [NIHSS], a modified-SOAR (mSOAR)), would improve the prognostic accuracy.  
 
Methods: Using Anglia Stroke & Heart Clinical Network data, 2008-2011, we assessed 
performance of SOAR and mSOAR against in-hospital mortality using area under the 
receiver operating curve (AUROC) statistics. We externally validated the prognostic utility 
of SOAR and mSOAR using an independent cohort dataset from Glasgow. We described 
calibration using Hosmer-Lemeshow goodness-of-fit test. 
 
Results: A total of 1002 patients were included in the derivation cohort, 105 (10.5%) died 
as in-patient. The AUROCs for outcome of early mortality derived from the SOAR and 
mSOAR were: 0.79 (95% confidence intervals [95%CI], 0.75-0.84) and 0.83 (95%CI: 0.79-
0.86), respectively, (p=0.001). The external validation dataset contained 1012 patients 
with stroke, of which 121 (12.0%) patients died within 90 days. The mSOAR scores 
identified risk of early mortality ranging from 3% to 42%. External validation of mSOAR 
yielded AUROC of 0.84 (95%CI: 0.82-0.88) for outcome of early mortality. Calibration was 
good (p=0.70 for the Hosmer-Lemeshow test).  
 
Conclusions: Adding NIHSS data to create a modified-SOAR score improved prognostic 
utility in both derivation and validation datasets. The mSOAR may have clinical utility by 
using easily available data to predict mortality.  
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INTRODUCTION:  
There are a growing number of prognostic models and scales designed to predict mortality 
or other outcomes following acute stroke.1-8 Although many of the scales have favorable 
properties reported, few have been  incorporated into routine clinial practice. Two 
common limitations in prognosis research are failure to modify scales with new covariates 
that may improve performance and lack of external validation of scales in independent 
cohorts.9 
 
The SOAR stroke score (stroke subtype [ischemic or hemorrhagic], Oxfordshire Community 
Stroke Project classification, age and pre-stroke modified Rankin scale) was recently 
proposed for early mortality prediction following an acute stroke.10, 11 The score may 
potentially be clinically useful due to its simplicity, with uncomplicated scoring rules and 
use of readily available data. Although, the prognostic accuracy of SOAR score in the 
original description was reasonable,10, 11 there was scope to improve further. The major 
limitation of SOAR is the lack of consideration of acute stroke severity marker. The best 
predictive values possible are needed to avoid giving patients and family wrong and 
potentially damaging prognostic information. An initial acute stroke severity score, 
National Institutes of Health Stroke Scale (NIHSS) on admission, is well established as an 
independent predictor of outcome post-stroke.12-14 Furthermore, the usefulness of SOAR 
beyond in-patient stay is not examined previously. 
 
In this paper, we aimed to evaluate whether including a measure of initial stroke severity 
(National Institutes of Health Stroke Scale [NIHSS]) to form a modified SOAR (mSOAR) 
score, would improve the prognostic accuracy and also assessed this would be applicable 
up to 90-days post stroke in an independent dataset.  
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METHODS 
The SOAR score 
The description for the original SOAR score’s derivation has been published elsewhere.11 
Briefly, the SOAR score is an 8-point scale (0-7) (Table 1). The total SOAR score is the sum 
of points allocated for each of the input variables, all measured at the time of admission.  
 
Derivation of modified-SOAR score (mSOAR) 
Data Source: We conducted a retrospective analysis on routine clinical database held as 
part of the Anglia Stroke & Heart Clinical Network (ASHCN), which recorded consecutive 
stroke admissions between 2008 and 2011 and followed till hospital discharge. The registry 
is in a geographical area of England and includes eight National Health Service (NHS) 
hospitals in Norfolk, Suffolk and Cambridgeshire. Of note, most in-hospital deaths in 
ASHCN occurred within 90-day; 81% of within 90 days deaths were in-hospital deaths in 
Anglia Stroke Network Evaluation Study (ASCNES)15  the participants of which were drawn 
from ASHCN database.  
 
All patients included were confirmed stroke cases aged 18 years and over based on expert 
multidisciplinary clinical assessment informed by neuroimaging and other investigations as 
per usual clinical practice. All included patients were treated as per institutional practice 
and stroke guidelines. Relevant Institutional & Ethical approvals of use of ASHCN data was 
obtained as part of ASCNES.15 Conduct and reporting of our analysis is in accordance with 
the UK Medical Research Council (MRC) PROGnosis RESearch Strategy (PROGRESS) 
Partnership best practice guidance.16  
 
Participants and variables 
We included patients for whom we had baseline demographic and outcome information to 
designate our prognostic scales and chosen outcome. Variables included to calculate SOAR 
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and mSOAR scales were: age (years), stroke subtype (ischemic or hemorrhagic, based on 
clinical and neuroimaging finding), OCSP classification (total or partial anterior 
circulation, posterior circulation or lacunar strokes), pre-stroke mRS and baseline NIHSS at 
the time of first assessment on hospital arrival. Outcome of interest was all cause 
mortality censored at discharge. The length-of-stay for individuals who lived was a median 
of 9 (interquartile range, IQR 5-19) days; and for those who died; 10 (IQR 5-27) days. 
 
External validation 
We validated mSOAR score performance using pooled data from two independent 
prospective observational studies performed in Glasgow, United Kingdom.17, 18 Process for 
the validation was equivalent to that employed in the derivation studies. We included 
those stroke patients with relevant baseline and 90 day mortality data. In one dataset, 
initial stroke severity was assessed using Scandinavian Stroke Scale (SSS) rather than 
NIHSS. We transformed SSS into NIHSS using a validated process.19 
 
Statistical Methods  
We used standard descriptive statistics for the cohort. We described mean (standard 
deviation, SD) or median (IQR) for continuous variables and count (percentage) for 
categorical variables. In order to assign an integer score for baseline NIHSS into the 
modified-SOAR score, we categorized the NIHSS scores into four categories; 1-4, 5-10, 11-
20 and ≥21. The designated integer values for baseline NIHSS was obtained by rounding the 
log-ORs to the nearest integer.15 To keep scoring aligned with original SOAR scores, we 
further collapsed NIHSS categories 11-20 and greater than (>)20 into a single category of 
>11. (Supplementary Table I) 
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We calculated odd ratios (ORs) and 95% confidence intervals (95%CI) for early (90 day) 
mortality using univariable and multivariable logistic regression models. Associated p-
values were calculated using the Cochrane-Mantel-Haenszel test.  
 
Outcome of interest is early mortality. We compared discrimination of SOAR and mSOAR 
using c-statistics (Area under the Receiver Operating Curve, [AUROC]) for each scale. We 
calculated the Net Reclassification Index (NRI) and the Integrated Discrimination 
Improvement (IDI) as a result of adding NIHSS to the original SOAR score. The NRI measures 
the correctness of reclassification of subjects based on their predicted probabilities of 
events using the new model with the option of imposing meaningful risk categories.20, 21 
The IDI measures the new model’s improvement in average sensitivity without sacrificing 
average specificity.20, 21 NRI and IDI are methods to measure the increase (or decrease) in 
predicted probabilities for those who have (or have not) an event of interest.20, 21  We 
assessed calibration using Hosmer-Lemeshow goodness-of-fit tests. We also performed the 
sensitivity analysis in the validation cohort for outcome of mortality within 10 days. 
 
Analyses were undertaken using SAS version 9.3 (SAS Institute, Inc, Cary NC) and Stata 
version 11.0 (Stata Corporation, College Station, TX, USA).       
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RESULTS 
Derivation cohort: Of the 8756 total acute stroke patients in the ASHCN registry (2008-
2011), we used data for 1002 (11%) patients, who had complete baseline data for 
individual items of the SOAR/ m-SOAR scores. The main missing variable was NIHSS as this 
was not routinely assessed. The characteristics of those with NIHSS observed and those 
with missing NIHSS data within the ASHCN registry during the study period are shown in 
Supplementary Table II. The cohort with complete baseline data to form the SOAR/ 
mSOAR scores had median age of 78 (IQR: 69-85) years; 465 (46%) were female; median 
baseline NIHSS of 6 (3-13). (Table 1)  One hundred and five (10.5%) patients died as in-
patient. (Table 2)  
 
The median SOAR score was 2 (IQR: 1-3). The proportions of early mortality post-stroke 
varied according to the original SOAR scores (Supplementary Table III).  
 
The median mSOAR score for the cohort was 3 (IQR: 2-5). The proportions of early death 
post-stroke varied according to individual modified-SOAR scores from 1% early mortality 
for mSOAR of 0-1 to 49% early mortality for mSOAR of 7. (Table 2)  The observed risks for 
increasing value of the mSOAR score in Table 2 were very similar to those predicted from 
the logistic regression model. The predicted value for each mSOAR scores, 0 to 7, were 
1.0%, 1.5%, 6.5%, 9.2%, 19.5%, 26.2% and 49.2%, respectively. These are very close to the 
observed risks and hence we have based our ‘predicted values’ on the observed risks of 
the derivation cohort. 
 
Prognostic accuracy metrics (sensitivity, specificity, positive and negative predictive 
values) for predicting early mortality varied according to mSOAR with a “trade-off” 
between sensitivity and specificity particularly evident at extremes of scoring. (Table 3) 
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The mSOAR score that appeared to show optimal prognostic accuracy was at cut-off score 
of 3 (i.e. mSOAR ≥4).  
 
The discrimination of the original SOAR and mSOAR scores, using AUROC, were 0.79 
(95%CI: 0.75-0.84) and 0.83 (95%CI: 0.79- 0.86), respectively, with a significant difference 
in favor of mSOAR (p=0.001). (Supplementary Figure I, Supplementary Figure II, and Figure 
1)  Calibration suggested that the mSOAR model gave reasonable fit to the data was good 
(p=0.67 for the Hosmer-Lemeshow test).  
 
Validation cohort: The two studies that comprised the external validation cohort included 
1091 patients of whom 1012 (93%) had full data to allow SOAR/ mSOAR scoring and 
outcomes analyses. The remaining patients were excluded due to missing data. The 
median age of the validation cohort was 71 (IQR: 61-79) years; with 497 (49%) were female 
and median baseline NIHSS was 5 (IQR: 2-11). (Table 1)  One hundred and twenty one 
(12.0%) patients died within 90 days post-stroke. (Table 2)  
 
The median original SOAR score for the validation cohort was 1 (IQR:1-2). In contrast, the 
median mSOAR score for similar cohort was 2 (IQR:1-4). The proportions of early death 
post-stroke varied according to mSOAR scores from 3% for mSOAR score of 0-1 to 42% for 
mSOAR of 7. (Table 2)  The AUROC of the modified-SOAR score performed using the 
validation cohort was 0.84 (95%CI: 0.82-0.88) for outcome of early mortality. Calibration 
suggested that the mSOAR model gave a reasonable fit to the data (p=0.70 for the 
Hosmer-Lemeshow test). (Figure 2) 
 
For the derivation cohort the NRI was 66.7% (n=547 recoded to a lower risk category and 
n=76 recoded to a higher risk category).  For the validation cohort the NRI was 62.5% 
(n=662 recoded to lower risk and n=78 recoded to higher risk).  (Supplementary Table IV 
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and V)  The IDI in sensitivity across all possible cut-offs is 4% for both of the original SOAR 
and mSOAR scores. 
  
Sensitivity analysis: Results of sensitivity analysis performed on the validation cohort for 
outcome of mortality within 10 days post-stroke are available in the Supplementary Table 
VI and Supplementary Figure III. Briefly, 98 (81%) patients died within 10 days post-stroke. 
The proportion of patients with 10 day mortality post-stroke according to mSOAR score 
mirrored the proportion of patients with 90 day mortality post-stroke, apart from patients 
who had the highest mSOAR score of 7. The AUROC of the mSOAR score for outcome of 
death within 10 days post-stroke was comparable with the AUROC of death within 90 days, 
0.81 (95%CI: 0.77-0.85) and 0.83 (95%CI: 0.79- 0.86), respectively. (Supplementary Figure 
III). 
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DISCUSSION 
Our findings suggest that the addition of an initial stroke severity scale (NIHSS) may 
significantly improve prognostic accuracy of the SOAR score for predicting early mortality 
post stroke. We believe our modified “mSOAR” score offers prognostic utility while 
remaining relatively easy to score.  A criticism of previous studies that have suggested 
favorable properties of prognostic tools has been lack of replication.  We performed 
validation analyses using an independent and geographically distinct population.  
Prognostic utility of mSOAR was confirmed in this cohort.  
 
Although several stroke prognosis scales are described few have been adopted for 
widespread clinical use.  An example of a prognostic tool that has translated into practice 
is the ABCD2 risk score for transient ischemic attack.22  We believe mSOAR shares several 
features with ABCD2 that should make it attractive to clinical teams.  The input covariates 
of mSOAR are easily available, in fact most of the features needed to score mSOAR are 
recorded as standard in national stroke audits.  We recognize that pre-morbid mRS is an 
imperfect measure but it remains the most common method of describing pre-stroke 
functioning.23  Further we and others have previously shown that pre-stroke mRS is an 
independent predictor of stroke outcomes such as mortality and length of stay.24, 25 
Creating a total mSOAR score is also straightforward with only five variables requiring 
scoring and no need for external software or complicated arithmetic.  Derivation and 
validation of mSOAR was based on a heterogenous population and so the score should be 
applicable to all stroke syndromes. 
 
Our study had a specific hypothesis around adding a marker of initial stroke severity to an 
existing prognostic tool.  We recognised that stroke impairment measures such as NIHSS 
have prognostic value as a standalone assessment and so intuitively adding these data to 
SOAR should improve properties.  Our approach could be applied to any of the other stand 
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alone or multivariate prognostic tools available in acute stroke.  Indeed, future prognostic 
research in stroke requires further examination of which are the best predictors of various 
relevant outcomes including mortality and functional outcome both as standalone and as 
part of multivariable predictive tools. Perhaps, inclusion of other covariates especially 
more sophisticated or clinically relevant variables would improve the prognostic value. For 
example, the addition of neuroimaging finding to the ABCD2 score22 (which resulted to 
ABCD3-I score26) improves the risk stratification after transient ischemic attack in 
secondary care settings.26 Another example is the widely used and well-validated ASTRAL 
score, which includes time delay from stroke onset to admission, specific clinical signs at 
presentation and baseline glucose level.8, 27 It would also be informative to compare 
clinical utility of mSOAR against intuition of an experienced clinician. Future prognostic 
research perhaps should focus on utilising large composite datasets with comprehensive 
baseline data which would allow for such an analysis and help describe an optimal 
predictive covariate sets for relevant outcomes. 
 
We describe an optimal performing cut point for our scale, this is the point of most 
equitable trade-off between false positives and false negatives.  In practice the mSOAR 
score that has greatest utility will vary according to the purpose for which the score is 
used.  For example, if clinicians wish to use the prognostic information to inform 
discussions around ceilings of care, they may prefer a cut point on the scale that 
minimises false positives. 
 
A difficulty with mSOAR and indeed all stroke prognostic scales is how the clinician uses 
the tool.  If decisions on pursuing or withholding treatment are to be based on a risk 
estimate then that estimate needs to be robust.  Although mSOAR has favorable 
properties, that are comparable or better than many other prognostic tools, it is probably 
still not suitable as the sole basis for therapeutic decisions.  Even at the optimal 
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performing cut point, mSOAR will suggest early mortality for a substantial proportion who 
go on to survive past ninety days and equally will suggest survival for a proportion who 
have early mortality.  Nonetheless patients and families want early prognostic information 
and clinicians have to make therapeutic decisions based on likely prognosis each day.  We 
believe mSOAR offers some structure and evidence base to inform prognostic assessment. 
 
We agree the Net Reclassification Index (NRI) appears high. The NRI works best for 
dichotomous data.20, 21  Majority of the re-classifications in our data were within the 'low 
risk' categories hence the practical importance of these re-classifications will be limited. 
Thus, we believe that the NRI should be interpreted with caution and prefer the ROC as a 
better measure of the difference between the risk scores. 
 
Strengths of our analysis include the large sample size, large number of “outcomes” and 
“real world” populations included. We believe our results will have greater external 
validity than prognostic scores derived and validated exclusively using selected clinical 
trial participants. Furthermore, for the first time we found SOAR and mSOAR are useful up 
to 90days post stroke mortality prediction. Despite the observable differences between 
the derivation and validation cohorts in terms of age and pre-stroke mRS, and the follow-
up time points (inhospital vs. within 90 days) the mSOAR score performed very similarly, 
and consistently which may indicate its generalizability.   
 
A limitation of our derivation dataset was substantial missing NIHSS data.  Our analysis 
comparing those with and without NIHSS suggests that missing NIHSS data were more likely 
to be associated with markers of poor outcome (age, pre-stroke mRS) and higher in-
hospital mortality, approximately doubled the mortality risk.  The data we used for our 
derivation work was from a clinical registry.  At the time of data collection NIHSS 
assessment and recording in the registry was not mandatory.  We acknowledge that those 
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with NIHSS recorded may be systematically different from those without, however the 
derivation cohort still has a spread of NIHSS and outcomes that are in keeping with data 
from other registries and so seem to have external validity.  The effect of missing NIHSS 
could potentially bias the prognostic properties of mSOAR, but we are reassured that in 
our validation cohort (with good data capture for NIHSS) properties of mSOAR were similar 
to the derivation data. We also hope that the effect of any misreporting of key variables 
will be modest given our relatively large and similar size datasets for derivation and 
validation; and the internal and external quality control employed within such national 
registries. The final cohorts are all old and changes in stroke care may have impacted on 
early mortality and hence the properties of the tool. Of note, the derivation data was 
based on in-hospital mortality and we were unable to ascertain their vital status at 90-
days. Nevertheless examination of ASCNES data (drawn from the same ASHCN database) 
with one year follow up data demonstrated that 81% of within 90 days were in-hospital 
deaths.  
 
In conclusion, our results demonstrate the reliability of modified-SOAR score to predict 
early death in an acute stroke cohort. Adding NIHSS data to the original SOAR score, to 
create modified-SOAR score, improved the prognostic utility in both derivation and 
validation datasets. Modified-SOAR may potentially help clinicians better predict early 
stroke mortality. 
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TABLES 
Table 1: Baseline characteristics of the derivation and validation cohorts, data are 
presented as per SOAR and mSOAR scoring. 
 Derivation  (N=1002), 
 n(%) 
Validation (N=1012), 
n(%) 
Age, median (IQR)   
≤65 191(19.1) 355(35.1) 
66-85 595(59.4) 563(55.6) 
>85 216(21.6) 94(9.3) 
Sex   
Female 465(46.4) 497(49.1) 
Stroke subtype   
Infarction (ischemic) 929(92.7) 924(91.3) 
   
OSCP classification   
LACS/PACS 661(66.0) 663(66.2) 
POCS 134(13.4) 93(9.3) 
TACS 207(20.7) 246(24.5) 
Pre-stroke mRS   
mRS 0-1 850(84.8) 877(86.7) 
mRS 2-3 139(13.9) 130(12.9) 
mRS 4-5 13(1.3) 5(0.4) 
Baseline NIHSS,   
NIHSS 0-4 363(36.2) 379(37.5) 
NIHSS 5-10 326(32.5) 303(29.9) 
NIHSS ≥11 313(31.2) 330(32.6) 
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OCSP indicates Oxford Stroke Classification Project; LACS: lacunar Stroke; PACS: partial 
anterior circulation stroke; POCS: posterior circulation stroke; TACS: total anterior 
circulation stroke, NIHSS: National Institutes of Health Stroke Scale. 
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Table 2: Comparison of derivation and validation results of modified-SOAR score. 
 Derivation cohort  Validation cohort  
Modified-SOAR 
score level 
Patient, 
n 
Patient with early 
mortality, n(%) 
Patient, 
n  
Patient with early 
mortality, n(%) 
0 or 1 205 2(1.0) 363  7(1.9) 
2 207 3(1.5) 211  6(2.8) 
3 200 13(6.5) 153  16(10.5) 
4 130 12(9.2) 103  18(17.5) 
5 113 22(19.5) 103  32(31.1) 
6 84 22(26.2) 67  37(55.2) 
7 63 31(49.2) 12 5(41.7) 
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Table 3: Predictive value of early mortality (death within 90 days) by modified-SOAR score using various cut-off points.  
Cut point n Early mortality, n (%) Sensitivity,% Specificity,% PPV,% NPV,% 
≥2 797 103 (12.9) 98.1 (93.3-99.8) 22.6 (19.9-25.5) 12.9 (10.7,15.5) 99.0 (96.5,99.9) 
≥3 590 100 (16.9) 95.2 (89.2-98.4) 45.4 (42.1-48.7) 16.9 (14.0-20.2) 98.8 (97.2-99.6) 
≥4 390 87 (22.3) 82.9 (74.3-89.5) 66.2 (63.0-69.3) 22.3 (18.3-26.8) 97.1 (95.4-98.2) 
≥5 260 75 (28.8) 71.4 (61.8-79.8) 79.4 (76.6-82.0) 28.8 (23.4-34.8) 96.0 (94.3-97.3) 
≥6 147 53 (36.1) 50.5 (40.5-60.4) 89.5 (87.3-91.4) 36.1 (28.3-44.4) 93.9 (92.1-95.4) 
≥7 63 31 (49.2) 29.5 (21.0-39.2) 96.4 (95.0-97.5) 49.2 (36.4-62.1) 92.1 (90.2-93.8) 
The parameters presented are for that score cut-off point and above with 95% confidence interval. PPV indicates positive predictive value; 
NPV: negative predictive value. 
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FIGURES and FIGURE LEGENDS 
Figure 1: Area under the receiving operator curve (AUROC) of the modified-SOAR score for 
early mortality in the derivation cohort. 
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Figure 2: Area under the receiving operator curve (AUROC) of the modified-SOAR score for 
early mortality in the validation cohort. 
 
 
 
Page 1 of 10 
 
SUPPLEMENTAL MATERIAL 
 
 
Online Supplement for manuscript entitled:  
 
Derivation and validation of a novel prognostic scale (modified-SOAR) to predict 
early mortality in acute stroke 
 
 
Authors:  
Azmil H Abdul-Rahim, MBChB, MRCP1 
Terence J Quinn, MD, MRCP1 
Sarah Alder, MBChB, MRCP2 
Allan B Clark, PhD3 
Stanley D Musgrave, MD3 
Peter Langhorne, PhD, FRCP1  
John F Potter DM, FRCP3 
Phyo K Myint, MD, FRCPE, FRCP4  
 
1 Institute of Cardiovascular and Medical Sciences, University of Glasgow, UK 
2 Aberdeen Royal Infirmary, NHS Grampian, UK 
3 Norwich Medical School, University of East Anglia, UK 
4 Epidemiology Group, School of Medicine and Dentistry, University of Aberdeen, UK. 
 
 
 
Supplemental Tables: I- VI 
 
Supplemental Figures: I-III 
  
Page 2 of 10 
 
SUPPLEMENTAL TABLES 
Supplementary Table I: Integer value assignment for the variable ‘baseline NIHSS’ to form 
the modified-SOAR prognostic score. 
Baseline 
NIHSS 
N Early death,  
n (%) 
Log-OR p-value Additional integer value 
to  the original SOAR score 
1-4 363 8 (2.2) 0 - 0 
5-10 326 22 (6.8) 0.86 0.046 1 
11-20 248 49 (19.8) 1.52 <0.001 2 
≥21 65 26 (40.0) 2.05 <0.001 2 
Univariable analysis for outcome of early mortality. NIHSS indicates National Institutes of 
Health Stroke Scale; OR: odds ratio. 
  
Page 3 of 10 
 
Supplementary Table II: Characteristics of patients with NIHSS observed and those within 
missing NIHSS data within the ASHCN registry (2008-2011). 
 NIHSS observed (n=1539) NIHSS missing (n=6218) p-value 
Age (years);  
mean ±sd  
74.8 ±12.9 76.7 ±13.0 <0.001 
Female; n(%)  728 (47.3) 3217 (51.7) 0.007 
Pre-stroke mRS; n(%)   <0.001 
0 736 (60.6) 1791 (48.3)  
1 181 (14.9) 635 (17.1)  
2 129 (10.6) 452 (12.2)  
3 107 (8.8) 450 (12.1)  
4 47 (3.9) 293 (7.9)  
5 13 (1.1) 88 (2.4)  
6 1 (0.1) 1 (0.0)  
Mortality within 
hospital admission 
of stroke 
159 (10.3) 1306 (21.0) <0.001 
Sd indicates standard deviation; mRS: modified Rankin scale.  
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Supplementary Table III: Proportions of early mortality (death within 90 days) according 
to the original SOAR score.  
 Derivation cohort  
Original SOAR 
score level 
Patient, 
 
n 
Patient with 
early mortality, 
n (%) 
0 or 1 346 7 (2.0) 
2 267 15 (5.6) 
3 179 22 (12.3) 
4 129 25 (19.4) 
5 61 24 (39.3) 
6 17 11 (64.7) 
7 3 1 (33.3) 
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Supplementary Table IV: Event and non-event reclassification in derivation cohort. 
 mSOAR 
score 
1 2 3 4 5 6 7  
Predicted 
event 
rate 
1.0% 1.5% 6.5% 9.2% 19.5% 26.2% 49.2% Total 
SOAR 
score 
  
Events, n 
1 2.0% 2 2 3 0 0 0 0 7 
2 5.6% 0 1 7 7 0 0 0 15 
3 12.3% 0 0 3 3 16 0 0 22 
4 19.4% 0 0 0 2 6 17 0 25 
5 39.3% 0 0 0 0 0 5 19 24 
6 64.7% 0 0 0 0 0 0 11 11 
7 33.3% 0 0 0 0 0 0 1 1 
 Total 
 
2 3 13 12 22 22 31 105 
                                               
                                          Non-events, n 
1 2.0% 203 95 41 0 0 0 0 339 
2 5.6% 0 109 95 48 0 0 0 252 
3 12.3% 0 0 51 52 54 0 0 157 
4 19.4% 0 0 0 18 31 55 0 104 
5 39.3% 0 0 0 0 6 7 24 37 
6 64.7% 0 0 0 0 0 0 6 6 
7 33.3% 0 0 0 0 0 0 2 2 
 Total 
 
203 204 187 118 91 62 31 897 
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Supplementary Table V: Event and non-event reclassification in validation cohort. 
 mSOAR 
score 
1 2 3 4 5 6 7  
Predicted 
event 
rate 
1.9% 2.8% 10.5% 17.5% 31.1% 55.2% 41.7% Total 
SOAR 
score 
 
 Events, n 
1 2.0%  7 4 9 0 0 0 0 20 
2 5.6% 0 1 4 13 0 0 0 18 
3 12.3% 0 0 2 3 23 0 0 28 
4 19.4% 0 0 0 0 0 26 0 26 
5 39.3% 0 0 0 0 1 2 3 6 
 Total 7 5 15 16 24 28 3 98 
 
   
Non Events, n 
1 2.0% 356 147 47 0 0 0 0 550 
2 5.6% 0 59 70 64 0 0 0 193 
3 12.3% 0 0 21 22 68 0 0 111 
4 19.4% 0 0 0 1 11 37 0 49 
5 39.3% 0 0 0 0 0 2 8 10 
6 64.7% 0 0 0 0 0 0 1 1 
 Total 356 206 138 87 79 39 9 917 
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Supplementary Table VI: Sensitivity analysis- Proportions death within 10 days according 
to the modified SOAR score.  
 Validation cohort  
Modified 
SOAR score 
level 
Patient, 
n 
Mortality within 
10 days of 
stroke,  
n (%) 
0 or 1 363 7 (1.9) 
2 211 5 (3.0) 
3 153 15 (9.8) 
4 103 16 (15.5) 
5 103 24 (23.3) 
6 67 28 (41.8) 
7 12 3 (25.0) 
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SUPPLEMENTAL FIGURE AND FIGURE LEGEND 
Supplementary Figure I: Area under the receiving operator curve (AUROC) of the original 
SOAR score for early mortality in the derivation cohort. 
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Supplementary Figure II: Area under the receiving operator curve (AUROC) of the original 
SOAR score for early mortality in the validation cohort. 
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Supplementary Figure III: Sensitivity analysis- Area under the receiving operator curve 
(AUROC) of the modified SOAR score for mortality within 10 days post-stroke in validation 
cohort. 
 
